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Objectives/Hypothesis: To report the clinical safety and efficacy of three-dimensional (3D)–printed, patient-specific,
bioresorbable airway splints in a cohort of critically ill children with severe tracheobronchomalacia.
Study Design: Case series.
Methods: From 2012 to 2018, 15 subjects received 29 splints on their trachea, right and/or left mainstem bronchi. The
median age at implantation was 8 months (range, 3–25 months). Nine children were female. Five subjects had a history of
extracorporeal membrane oxygenation (ECMO), and 11 required continuous sedation, six of whom required paralytics to main-
tain adequate ventilation. Thirteen were chronically hospitalized, unable to be discharged, and seven were hospitalized their
entire lives. At the time of splint implantation, one subject required ECMO, one required positive airway pressure, and 13 sub-
jects were tracheostomy and ventilator dependent, requiring a median positive end-expiratory pressure (PEEP) of 14 cm H2O
(range, 6–20 cm H20). Outcomes collected included level of respiratory support, disposition, and splint-related complications.
Results: At the time of discharge from our institution, at a median of 28 days postimplantation (range, 10–56 days), the
subject on ECMO was weaned from extracorporeal support, and the subjects who were ventilated via tracheostomy had a
median change in PEEP (discharge–baseline) of −2.5 cm H2O (range, −15 to 2 cm H2O, P = .022). At median follow-up of
8.5 months (range, 0.3–77 months), all but one of the 12 surviving subjects lives at home. Of the 11 survivors who were tra-
cheostomy dependent preoperatively, one is decannulated, one uses a speaking valve, six use a ventilator exclusively at night,
and three remain ventilator dependent.
Conclusions: This case series demonstrates the initial clinical efficacy of the 3D-printed bioresorbable airway splint
device in a cohort of critically ill children with severe tracheobronchomalacia.
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INTRODUCTION
Tracheobronchomalacia is a condition of dynamic
collapse of the trachea or bronchi during respiration.
Diagnosis is typically made via bronchoscopy. Mild forms
manifest as a cough, wheeze, or impaired secretion clear-
ance. Severe forms have reported mortality rates up to
80%.1 Tracheobronchomalacia can be idiopathic or associ-
ated with prematurity, cartilaginous, or other genetic
syndromes, congenital cardiovascular anomalies, or tra-
cheoesophageal fistulas.2,3
Current therapies for severe tracheobronchomala-
cia include tracheostomy with prolonged mechanical
ventilation,4 aortopexy,5 tracheobronchopexy,1,6 and intra-
luminal metallic,7,8 silicone,9 or bioresorbable10–12 stents.
However, these options carry a significant risk of morbidity
and mortality, variable efficacy, and a subset of children still
suffer acute life-threatening events despite these interven-
tions. In one study of 47 children with tracheobronchomala-
cia hospitalized in an intensive care setting, 28 (60%) died.3
For all but severe cases, if a child can be supported
for 24 months, natural airway growth and maturation
resolves symptoms.4 We have developed a three-dimensional
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(3D)–printed, externally-implanted, bioresorbable airway
splint that provides luminal support for at least two years,
and is subsequently resorbed, obviating the need for surgical
removal. Results of the first patient,13 and then the first
three patients were reported previously14; here we report
clinical outcomes of all 15 children who received splints at
our institution through July 2018.
MATERIALS AND METHODS
Patient Selection
Only children who were at high risk of death or permanent
disability were considered for airway splinting. This included life-
threatening events associated with tracheobronchomalacia, mechan-
ical ventilation requiring prolonged sedation, and airway erosion.
Cross-disciplinary consultation was utilized to ensure that airway
splinting did not constitute futile care. Children were not excluded
for tracheobronchomalacia distal to the areas able to be splinted,
severe concomitant pulmonary/cardiovascular disease, extracorpo-
real membrane oxygenation (ECMO) status, or underlying cartilagi-
nous disorders. Although tracheobronchomalacia is more frequently
characterized by circumferential collapse due to weakness of the
anterior (cartilaginous) airway, it can also be caused by intrusion of
the posterior (membranous) airway. Patients were not excluded
based upon type of tracheobronchomalacia. Patients with only one
lung were also not excluded.
Splint Design, Manufacturing Process, and
Regulatory Process
The splint design and fabrication process has been detailed
previously.14,15 Briefly, preoperative inspiratory/expiratory com-
puted tomography (CT) and bronchoscopy were performed to
confirm the diagnosis and location of tracheobronchomalacia.
Inspiratory and expiratory patient airway models were gener-
ated from CT data using Mimics Innovation Suite (Materialise
NV, Leuven, Belgium) to determine malacic segment length
and diameter; splint designs were then automatically generated
from these input data with Custom MATLAB (MathWorks,
Natick, MA) code, and subsequently test fit on the patient
models. Splints were then 3D printed from 96% polycaprolac-
tone/4% hydroxyapatite via laser sintering, and sterilized via
ethylene oxide (Nelson Laboratories, Salt Lake City, UT).
Permission from the Food and Drug Administration (FDA) and
our institutional review board (IRB) was obtained for each case via
the FDA Expanded Access pathway (compassionate use). Informed
consent was obtained from each patient’s parent or guardian.
Surgical Technique
Preoperative bronchoscopy was performed to evaluate the
airway. A median sternotomy with or without a cervical incision
was performed. The anterior and lateral aspects of the trachea
and/or mainstem bronchi were isolated, and the area(s) of
malacia were confirmed. After choosing the splint(s) of best fit, a
series of partial thickness polypropylene sutures were placed cir-
cumferentially around the malacic segment(s). The sutures were
then passed through the interstices of the splint, and the splints
were parachuted down onto the airways. The sutures were then
tied, suspending the trachea/bronchi within the splint. Surgical
clips denoted proximal and distal ends of the splints for radio-
graphic studies. If the child required concomitant cardiac repair,
this was completed after splint implantation. Intraoperative
bronchoscopy confirmed patency of the splinted regions.
Data Collection
For the duration of the study, parents and referring physi-
cians were queried for clinical updates. Once patients surpassed
≥1 year after implantation, families were invited to enroll in a
formal survey study to collect information about hospitalizations,
illnesses, or adverse events. Separate IRB approval and research
consent were obtained for this study.
Statistical Analysis
Respiratory variables, length of hospitalization, age at
implantation, and length of follow-up were collected. For this series
of 15 patients, data were descriptive and reported as medians and
ranges. For the 12 patients with positive end-expiratory pressure
(PEEP) measurements both preoperative and at discharge from our
institution, and the nine with PEEP measurements at last follow-up
(i.e., on positive pressure ventilation), differences were calculated
and the median change was compared to zero via the sign test.
McNemar’s test compared pre- to postsurgical numbers of patients
with chronic hospitalization and ECMO or continuous ventilation
for the 12 patients with both measures. The cumulative incidence
function of the time (months) to discontinuation of daytime mechan-
ical ventilation was estimated and plotted using an unadjusted
Fine-Gray model16 in the presence of competing risks (death).
RESULTS
From February 2012 to July 2018, 29 splints were
implanted in 15 children. Median age at implantation
was 8 months (range, 3–25 months). Nine children were
female. The median follow-up was 8.5 months (range,
0.3–77.1 months). Implanted splints included 10 (35%)
tracheal, 12 (41%) left mainstem bronchus (LMB), and
seven (24%) right mainstem bronchus (RMB) splints. The
LMB was more commonly splinted than the RMB, sec-
ondary to an increased incidence of vascular compression.
Ten children had splints implanted in more than one
location. The average sizes of the tracheal, LMB, and
RMB splints were (inner diameter × length in millime-
ters): 13.3 × 21.2, 8.7 × 13.0, and 9.4 × 9.1, respectively.
Comorbidities and indications for airway splinting
are presented in Table I. The primary indication for splint-
ing was cardiopulmonary life-threatening events in
12 patients (including five with a history of ECMO), life-
threatening tracheostomy tube erosion and failure to wean
from mechanical ventilation in one patient, failure to wean
from mechanical ventilation in one patient, and social fac-
tors necessitating avoidance of a tracheostomy in one
patient. All patients had previous surgical attempts to
address tracheobronchomalacia, and all but one was tra-
cheostomy and ventilator dependent. Eleven patients
required sedation to maintain adequate ventilation, and of
those, six also required paralytics. Thirteen patients were
hospitalized in an intensive care setting prior to transfer to
our institution, unable to be discharged home, and seven
had been hospitalized their entire life. Six patients were
born before 37 weeks of gestation. Two children had congen-
ital absence of the right lung and had previously underdone
long-segment slide tracheoplasties for tracheal stenosis.
All 15 patients had intrathoracic tracheobronchoma-
lacia, and a median sternotomy was performed, 10
of which were re-sternotomies. Two patients also had
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tracheobronchomalacia that extended just distal to the
tracheostomy stoma, and a cervical incision was also per-
formed. Three patients had solely or predominantly pos-
terior tracheobronchomalacia.
Cardiopulmonary bypass is not required for splint
placement, except as indicated for cardiorespiratory instabil-
ity. Bypass was used during splint placement in the first
five patients and for only one of 10 subsequent patients.
One child had splints placed while on ECMO. Eight patients
had cardiac or vascular defects that were addressed during
the same surgery immediately after splint placement. Age
and year of implantation, and preoperative clinical status
are presented in Table II. No patient required splint
removal or reoperation for their splint(s).
Preoperatively, all but one patient were tracheostomy
and ventilator dependent, requiring a median PEEP of
14 cm H2O (range, 6–20 cm H2O). Of the 13 patients dis-
charged from our institution who were initially ventilator
dependent, one no longer required mechanical ventilation,
whereas the median PEEP for the remaining 12 was 8 cm
H2O (range, 5–14 cm H2O) at a median of 28 days postop-
eratively (range, 10–56 days). For the 12 patients with pre-
operative and discharge PEEP measures, discharge PEEP
levels were significantly lower, with a median change from
discharge to preoperative of −2.5 cm H2O (range, −15 to
2, P = .022). In total, 12 patients were transferred back to
their referring institution, two were discharged home,
and one died prior to discharge. At a median follow-up of
8.5 months (range, 0.3–77 months), 12 patients are long-
term survivors, and all but one (a recent case) live at
home. Among nine patients who still have a tracheostomy
at last follow-up, PEEP values (daytime) continued to
decrease, with a median change from most recent to pre-
operative of −14 cm H2O (range, −16 to −4 cm H2O,
P = .004). A summary of preoperative and postoperative
clinical outcomes are listed in Tables II and III. At last
follow-up, of the 12 survivors, one patient remains hospi-
talized, and only three require continuous mechanical
ventilation (Fig. 1). Median time to discontinuation of
daytime mechanical ventilation (or cumulative incidence
TABLE I.
Comorbidities and Indications for Airway Splinting.
Case Comorbid Diagnoses
Indications for Splint Implantation
History of
ECMO
Cardiopulmonary
Arrest Requiring
Compressions
Bag–Mask
Ventilation Other
1 Criss-cross branch pulmonary arteries, moderate hypoplasia of
RPA, tortuous ascending aorta, born at 35-weeks of gestation
Yes Yes
2 s/p TOF/APV repair, 22q11 deletion, renal tubular acidosis,
protein-losing enteropathy
Yes
3 s/p TOF/APV repair and tracheal stenosis resection, failure to
thrive
Yes Yes
4 s/p hypoplastic arch reconstruction and PAB placement, s/p
takedown of PAB and VSD closure, residual VSD, SubAS,
chromosomal abnormality
Yes Yes
5 s/p TOF/APV repair, 22q11 deletion syndrome, s/p metallic
bronchial stent placement
Yes Yes Yes
6 s/p aortopexy Yes Yes
7 HLHS, s/p Norwood, s/p H-type tracheoesophageal fistula repair Yes Yes Yes
8 Complete AVSD, dextrocardia, heterotaxy with polysplenia,
anomalous systemic and pulmonary venous return, pulmonary
artery stenosis, s/p pacemaker placement for heart block
Unable to wean off ventilator; in
need of complex cardiac repair
9 s/p congenital diaphragmatic hernia repair, VSD, s/p PDA
ligation, pulmonary hypertension, tracheal erosion in region of
innominate, born at 35 weeks of gestation
Tracheal erosion caused by long-
term mechanical ventilation
10 Born at 26 weeks of gestation, bronchopulmonary dysplasia,
pulmonary hypertension, grade I IVH
Yes
11 s/p congenital diaphragmatic hernia repair, right lung agenesis,
pulmonary hypertension, long segmental tracheal stenosis s/p
slide tracheoplasty; born at 36 + 6/7 weeks of gestation
Yes Yes
12 Meier-Gorlin syndrome Yes Yes
13 Unrepaired TOF/APV, PKU embryopathy, micrognathia,
microcephaly, horseshoe kidney, cleft palate, s/p
laryngotracheal reconstruction; born at 36 weeks
Yes Yes
14 Right lung agenesis, long-segment tracheal stenosis s/p slide
tracheobronchoplasty, and s/p aortopexy
Yes Yes
15 Chronic lung disease, multiple ventricular septal defects s/p
repair, mitral stenosis, hypoplastic aortic arch with coarctation
of the aorta s/p repair. Born at 29 weeks of gestation
Yes Desire to avoid a tracheostomy
due to social and logistical
concerns
ECMO = extracorporeal membrane oxygenation; RPA = right pulmonary artery; s/p = status post; TOF/APV = tetrology of fallot with absent pulmonary
valve; PAB = pulmonary artery band; VSD = ventricular septal defect; SubAS = subaortic stenosis; HLHS = hypoplastic left heart syndrome; AVSD = atrioventric-
ular septal defect; IVH = intraventricular hemorrhage; PKU = phenylketonuria.
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of time to daytime ventilator discontinuation in the pres-
ence of competing risks [death]) is 12.0 months (Fig. 2).
Severe lobar and/or segmental malacia (distal to mainstem
bronchi) was a common finding in children unable to discon-
tinue ventilator support.
Serial magnetic resonance imaging (MRI) was per-
formed in case 1. MRI demonstrated intact splint at 6 and
12 months postoperatively, but evidence of degradation at
38 and 49 months postoperatively (Fig. 3). Representative
preoperative and postoperative minimum intensity projec-
tion generated images from the expiratory CT scans are
presented in Figure 4.
No child required removal or replacement of their
splint(s). As of July 2018, the first four children to receive
splints are more than 2 years past splint implantation; all
are alive with sustained significant clinical benefit. One
child later required an aortopexy 2.5 years after splint
implantation and subsequently discharge home due to
moderate malacia distal to the splinted region.
Complications
Among the 15 patients receiving 29 splints, there were
two complications related to surgical dissection. One entry
into the tracheoesophageal fistula repair pouch occurred
and was closed primarily. During another dissection, the
trachea and mainstem bronchi were both entered at multi-
ple sites due to the extremely thin airway wall, associated
with the patient’s underlying Meier-Gorlin syndrome. This
resulted in two dehiscences, which continue to heal while
the patient remains on oral antibiotics.
There were three mortalities. Two patients died with
patent airways due to non–splint-related causes. One
patient died 7 months after implantation after suffering an
arrest secondary to diffuse hemoptysis, a rare, but known,
complication of single ventricle anatomy.17 An autopsy con-
firmed the presence of many prominent congested submuco-
sal vessels and abnormal dilated tortuous veins well away
from the splints. A second patient died 10 days postopera-
tively with airways that were patent in the splinted region,
after suffering an arrest secondary to CO2 retention and aci-
dosis, complicated by reactive pulmonary hypertension
related to parenchymal disease in her single lung.
One patient died of a possible splint-related compli-
cation from upper gastrointestinal hemorrhage 6-months
postoperatively. Postmortem evaluation revealed that the
tracheal splint was displaced from its original position
and eroded into the esophagus. The patient’s other splint
TABLE II.
Age and Year of Implantation and Preoperative Status of the Splint Patients.
Patient
Age at
Implantation,
mo
Year of
Implantation
Preoperative Status
Respiratory Status
PEEP,
cm H20
Required
Sedation to
Maintain
Ventilation?
Required
Paralytics
to Maintain
Ventilation?
Predominantly
Posterior
Malacia? Living Situation
1 3 2012 Trach and vent dependent 14 Continuous Yes No PICU for 1.5 months
2 16 2014 Trach and vent dependent 20 Continuous Yes No NICU/PICU for entire life
(16 months)
3 5 2014 Trach and vent dependent 10 Continuous No No PICU for 3 months
4 10 2015 Trach and vent dependent 10 Continuous Yes No PICU for 2 months
5 5 2016 Trach and vent dependent 14 Continuous Yes No NICU/PICU for entire life
(5 months)
6 4 2016 Trach and vent dependent 16 Continuous No No NICU/PICU for 3 months
7 8 2016* Trach and vent dependent 10 Continuous No Yes NICU/PICU for entire life
(8 months)
8 25 2017* Trach and vent dependent 6 No No No Home, previous long
hospitalizations
9 16 2017 Trach and vent dependent 14 No No No Home, previous long
hospitalizations
10 9 2017 Trach and vent dependent 14 Continuous No Yes NICU/PICU for entire life
(9 months)
11 6 2017* Trach and vent dependent 14 Continuous No No PICU for 2 months
12 6 2018 Trach and vent dependent 18 Continuous Yes No NICU/PICU for entire life
(6 months)
13 11 2018 Trach and vent dependent 14 No No Yes Hospitalized entire life
(11 months)
14 4 2018 Trach and vent dependent,
on ECMO at the time of
splint implantation
On ECMO Continuous Yes No NICU/PICU entire life
(4 months)
15 13 2018 HFNC during the day,
CPAP at night.
8 (CPAP mask
at night)
No No No Hospitalized for 4 months
CPAP = continuous positive airway pressure; ECMO = extracorporeal membrane oxygenation; HFNC = high-flow nasal cannula; NICU = neonatal intensive
care unit; PEEP = positive end-expiratory pressure; PICU = pediatric intensive care unit;
*Follow-up ends at death.
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was in its expected location. She was also found to have
gastric erosions. Autopsy was not able to define the
source of the hemorrhage.
Length of Hospitalizations
Median length of hospitalization prior to transfer to
our institution was 113 days (range, 0–501 days). Seven
patients were hospitalized their entire lives prior to
transfer to our institution. Median length of hospitaliza-
tion at our institution was 45 days (range, 12–72 days),
with the first 14 days occupied by medical assessment
and designing, manufacturing, and sterilizing the airway
splints for patients who were chronically hospitalized
(n = 13) and unable to wait at home during splint manu-
facture. Two patients were discharged directly home from
TABLE III.
Postoperative Status of the Splint Patients.
Status as of July 2018 (Postoperative)
Patient Respiratory Status
Current
PEEP, cm H20
Required Sedation
to Maintain Ventilation?
Required Paralytics
to Maintain Ventilation? Current Disposition
1 Speaking valve all day Day 0, night: 0 No No Home
2 Decannulated None No No Home
3 Trach dependent; vent dependent at
night only
Day: 0, night: 8 No No Home
4 Trach dependent; vent dependent at
night only
Day 0, night: 6 No No Home
5 Trach and vent dependent 10 No No Home
6 Trach dependent; vent dependent at
night only
Day: 0, night: 8 No No Home
7 Died 6.8 months postoperatively with
patent airways; cause: underlying
congenital heart disease
N/A Before terminal
decline, no
Before terminal
decline, no
Deceased
8 Died 6 months postoperatively with
patent airways; cause: upper
gastrointestinal hemorrhage
N/A Before death, no Before death, no Deceased
9 Trach dependent; vent dependent at
night only
Day 0, night: 6 No No Home
10 Trach dependent; vent dependent at
night only
Day: 0, night: 8 No No Home
11 Died at 10 days postoperatively with
patent airways; cause: underlying
parenchymal (single) lung disease
N/A Prior to death, yes Prior to death, yes Deceased
12 Trach and vent dependent 6 No No Home
13 Trach dependent; vent dependent at
night only
Day 0, night: 6 No No Home
14 Trach and vent dependent 14 (weaning) Yes, weaning No PICU
15 Nasal cannula during the day and
night
None No No Home
N/A = not applicable; PEEP = positive end-expiratory pressure; PICU = pediatric intensive care unit.
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Fig. 1. The number of patients who were chronically hospitalized and who had continuous mechanical ventilation or ECMO, pre- versus post-
operatively. The number on top of the bar is the frequency. The 15 children are included preoperatively and 12 postoperatively. *P < .01.
ECMO = extracorporeal membrane oxygenation.
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our institution at a median of 23 days (range, 11–35 days)
following implantation. For the 10 patients who were dis-
charged from their referring institution after back-transfer
from our institution, the median length of hospitalization at
the referring institution was 62 days (range, 1–285 days).
The median total length of hospitalization from splint
implantation to discharge home for the 12 patients who
survived and were discharged was 73 days (range,
11–315 days).
DISCUSSION
The severity of pediatric tracheobronchomalacia var-
ies widely. The diagnosis of tracheobronchomalacia is often
suspected based on clinical signs and symptoms such as
an expiratory wheeze that simulates recalcitrant asthma.
However, these clinical findings are neither sensitive nor
specific. Endoscopic evaluation remains the gold standard
for diagnosis, with flexible bronchoscopy during spontane-
ous breathing being preferred. In general, >50% narrowing
of the airway is accepted as diagnostic of tracheomalacia,
but classification of severity beyond that remains subjec-
tive and ill-defined.18,19 In addition to diagnostic bronchos-
copy, contrast expiratory/inspiratory CT can aid in
identifying specific regions of collapse, degree of distal
malacia, and any vascular anomalies.20,21
Children with mild TBM typically become asymptom-
atic after 2 years of age, often with no intervention
required. Moderate cases can be treated conservatively
with pharmacotherapy, including low-dose inhaled ipratro-
pium or bethanechol, along with chest physiotherapy to
improve secretion clearance and treatment of respiratory
infections. Moderate-to-severe cases may be managed with
continuous positive airway pressure (CPAP) to provide a
distending pressure to the airways and prevent collapse on
exhalation. More severe cases often present with recurrent
pneumonias requiring hospitalization, inability to extubate
following illness or procedures, or life-threatening events.
These cases may require surgical intervention, which
includes aortopexy, tracheobronchopexy, or tracheostomy
with or without mechanical ventilation.
A tracheostomy with or without mechanical ventila-
tion is the most common treatment for moderate to severe
tracheobronchomalacia. The tracheostomy tube can bypass
proximal tracheomalacia and can stent open the mid tra-
chea. A ventilator can then deliver positive pressure to
pneumatically stent open the more distal airways. This
treatment provides respiratory support until the child can
outgrow their malacia as the airway enlarges and the car-
tilage in their airways strengthens.2,4 Complications such
as delay in initiation of oral feedings,22 developmental
delay, and delay in speech and language development have
been reported, along with sudden death at home.4,22 In
one study of 32 premature infants and 18 full-term infants
with tracheobronchomalacia, a tracheotomy was required
in 24 (75%) of the preterm and seven (39%) of the full-term
infants.4 In these patients, CPAP was used in the manage-
ment of all of the premature patients and in three (43%) of
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Fig. 2. The cumulative incidence function of the time (months) to dis-
continuation of daytime mechanical ventilation using an unadjusted
Fine-Gray model in the presence of competing risks (death). Seven
children were able to discontinue daytime mechanical ventilation within
a year of airway splint implantation. [Color figure can be viewed in the
online issue, which is available at www.laryngoscope.com.]
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Splint Degradation by Serial MRI
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0
Fig. 3. In serial MRI of patient 1, the splint is represented by a signal void surrounding the left main bronchus. The splint is intact at 6 months
and 12 months postoperatively, but shows evidence of degradation at 38 months and 49 months. The yellow star indicates the lumen of the
unsplinted RMB. The blue star indicates the lumen of the splinted LMB. MRI = magnetic resonance imaging; LMB = left mainstem bronchus;
RMB = right mainstem bronchus. [Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]
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the seven full-term infants with a tracheotomy.4 The aver-
age duration of CPAP was 21.4 months for the premature
infants and 22.0 months for the full-term infants. There
were three deaths in the series.
For the most severe cases, tracheostomy with mechani-
cal ventilation even at extremely high PEEP is often inade-
quate. In the current study, out of the 14 children with a
tracheostomy preoperatively, 13 were experiencing cardio-
pulmonary life-threatening events despite mechanical venti-
lation and high levels of PEEP.
Standard anterior aortopexy is commonly used to
treat moderate-to-severe tracheobronchomalacia. Aorto-
pexy entails suturing the ascending aorta or aortic arch
to the posterior aspect of the sternum. Due to the approx-
imation of the anterior tracheal wall and posterior aorta,
this surgery may improve tracheal patency. A meta-
analysis of 581 children who received aortopexy for tra-
cheobronchomalacia found that 80% showed significant
clinical improvement, 8% showed no improvement, 4%
had a worsening of their symptoms, and 6% died at a
median follow-up of 47 months.5 However, aortopexy has
a high failure rate, particularly for severe cases such as
the patients in our series.
Others have tried posterior aortopexy—suturing the
descending aorta to the thoracic vertebrae—to address left
mainstem bronchomalacia. Unfortunately, in the largest
Fig. 4. The location of malacia has varied between patients, as shown in the minimum intensity projections generated from the preoperative
(left) and postoperative (right) expiratory computed tomography scans. Patient 5 had severe tracheobronchomalacia, patient 10 had complete
expiratory collapse of the midtrachea (red arrow) (10A), and patient 13 had paracarinal malacia and right mainstem bronchomalacia (red arrow).
All improved on postsplint images (5B, 10B, and 13B). All images were acquired with the tracheostomy tube removed except for image 13B.
[Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]
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study of this technique, eight out of 18 of children were
found to have residual severe left mainstem bronchomala-
cia requiring a tracheostomy (n = 1) or placement of inter-
nal stents (n = 7).23
Jennings has pioneered tracheobronchopexy,6 in
which the posterior (membranous) trachea is sutured to
the anterior spinal ligament and/or the anterior (cartilag-
inous) trachea and/or bronchi are sutured to the sternum.
In a recent case series, authors report no early or late
deaths.6 A two-stage approach is often required, as is
mobilization of the esophagus. Although the technique
appears to be efficacious in the trachea and right main-
stem bronchus, left mainstem bronchomalacia was relieved
in only two out of seven cases.6 In contrast, our external
splint has been equally effective for the trachea and both
mainstem bronchi. In addition, in comparison to our
cohort, the patients who received tracheobronchopexy were
less critically ill than our cohort. In a later case series by
the same group, 13% of their patients had apparent life-
threatening events preoperatively, considerably less than
our cohort, of whom 86% had documented cardiopulmo-
nary life-threatening events.24
In cases where tracheostomy with mechanical venti-
lation has failed or is contraindicated, other experimen-
tal treatments such bioresorbable, silicone, and metallic
stenting7–12 have been utilized, with varying degrees of
success. Internal stenting for tracheobronchomalacia carries
significant risk of device migration and obstruction of the
airway with silicone stents,9 and formation of granulation
tissue with resultant airway obstruction with metallic
stents.25 Bioresorbable internal stents may require serial
stenting and involves careful surveillance due to the short
resorption time and possible device migration.10
Various forms of external splinting have been
attempted for severe tracheobronchomalacia refractory to
traditional supportive treatment.26,27 As early as 1968,
ribs were used to externally splint the trachea.28,29 In the
late 1970s through the 1980s, Filler and colleagues used a
silicone elastomer (Silastic) reinforced polypropylene mesh
(Marlex) splint, which was applied externally to the air-
ways with mixed results.28,30–32 More recently, groups in
Germany and Japan described techniques to treat pediat-
ric tracheobronchomalacia via external airway stabiliza-
tion using polytetrafluoroethylene (PTFE) prostheses.26,33
Specifically, Ando et al. reported 98 patients undergoing
127 external PTFE airway stents at a mean age of
7.2 months.26 In this series, there were 14 deaths (14%),
including six (6%) that were possibly or definitely device-
related, with twelve patients (12%) requiring reoperations,
nine for restenosis and three for removal due to perfora-
tion of the airway. In comparison, we report three deaths
(20%) in our cohort, one of which was possibly device-
related (7%), but in a more severe clinical population com-
pared to the PTFE series (86% vs. 37% with documented
cardiopulmonary life-threatening events). No patient in
our cohort required splint reoperation.
Limitations
This is a nonrandomized case series with histori-
cal data for comparison of outcomes. All patients were
medically complex, with significant comorbidities and
prior cardiac, airway, and other interventions. In some
cases, concurrent cardiac repair was performed. These
factors may confound determining the influence of our
device on clinical outcomes. The extent to which the
data can be extrapolated to a less critically ill patient
population is unknown.
CONCLUSION
The study presents the clinical results of 15 patients
treated with 3D-printed, patient-specific, externally
implanted, bioresorbable airway splints. The overall device-
related complication and mortality rates were low in this
population of critically ill, medically complex patients. All
surviving patients experienced significant clinical benefit. A
pivotal clinical trial is planned in pursuit of FDA approval
and subsequent broader application.
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